This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
AT278 – Ultra-Concentrated Rapid Acting Insulin
- Potential to be the first concentrated rapid acting prandial insulin for insulin resistant diabetic patients
- Critical to enable next generation miniaturised insulin pump devices
- Potential to enable more effective disease management in patients needing high daily doses of insulin
AT278 – Ultra-Concentrated Rapid Acting Insulin
AT278 is an ultra-concentrated novel formulation of rapid acting insulin that has been designed to accelerate the absorption of insulin post injection. AT278 has the potential to provide the clinical benefits of a rapid acting insulin to patients who have high daily insulin requirements (>200 units/day) via a single injection and is also a critical step towards the advancement of the miniaturisation of next generation insulin delivery devices.
AT278 has the potential to be the first concentrated rapid acting insulin available for patients.
The Medical Need
There is a high unmet need for a stable, rapid-acting, ultra-concentrated insulin of up to 1000 U/mL, that can enable more effective disease management for those people with diabetes requiring >200 U/day.
An ultra-concentrated product is key for the miniaturisation of insulin delivery devices. Next-generation device technology such as wearable, continuous administration patch pumps and implants, are critical future developments for people living with diabetes. In particular, these devices offer the potential to improve compliance in difficult to treat groups such as children and teenagers. Such deliver systems when combined with a rapid acting insulin could improve glycaemic control and compliance, thereby reducing adverse events, as well as overall complications and morbidity.
As yet, there are no concentrated (>200U/mL) rapid acting insulin products on the market.
The Market
Diabetes is a large and growing market:
- Currently there are ~ 463m people with diabetes, with ~56m insulin users and a $22bn global insulin market¹
- By 2040 there will be an estimated 700m diabetics¹
Whilst there are rapid acting insulins available on the market, there remains a significant need for faster acting insulins as diabetes care advances towards more personalised treatment regimes and sophisticated drug/device combinations such as the automated Artificial Pancreas system.
Next generation delivery products will increasingly be miniaturised and require both concentrated and faster-acting insulin:
- Reduces the number of injections required each day for high dose patients
- Patch pumps and smaller devices offer the potential to significantly improve patient adherence, particularly for children and teenagers
- Automated artificial pancreas could remove the burden of self-management altogether
¹International Diabetes Federation, Diabetes Atlas, 2019